Acquiring Company
Neuphoria Therapeutics
Acquired Company
Scancell
Burlington
OxfordBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnologyHealth CareTherapeuticsDescription
Scancell Holdings is set to merge with Neuphoria Therapeutics in a reverse takeover. This merger allows Scancell to list on Nasdaq while retaining significant ownership. The combined entity aims to access deeper US biotech markets with a funding boost of up to $89 million.
Quick answer
Neuphoria Therapeutics is acquiring Scancell, announced July 24, 2026. Neuphoria Therapeutics is based in Burlington, Massachusetts, United States.
- How much did Neuphoria Therapeutics pay for Scancell?
- The deal value was not disclosed.
- What does Neuphoria Therapeutics do?
- Neuphoria Therapeutics Inc. is a Delaware corporation focused on innovative therapeutics.
- Where are Neuphoria Therapeutics and Scancell based?
- Neuphoria Therapeutics is based in Burlington, Massachusetts, United States. Scancell is based in Oxford, England, United Kingdom.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals (August 6, 2026)
- Tarsus acquires iRenix Medical for IRX-101 development (July 8, 2026)
- Aurinia completes acquisition of Kezar Life Sciences (August 29, 2026)
- Jazz Pharmaceuticals acquires Actio Biosciences (August 10, 2026)
- Supernus to merge with Indivior Pharmaceuticals (August 3, 2026)
- Bristol-Myers acquires Medarex for cancer pipeline (August 2, 2026)
Who to call at Neuphoria Therapeutics, and when
When Neuphoria Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Neuphoria Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Neuphoria Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Neuphoria Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Neuphoria Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Scancell?
Scancell was acquired by Neuphoria Therapeutics, based in Burlington. The deal was reported on July 24, 2026. Neuphoria Therapeutics Inc. is a Delaware corporation focused on innovative therapeutics. The company is dedicated to advancing treatments in the healthcare sector. Neuphoria Therapeutics is publicly traded (NEUP) and operates in Biotechnology.
When did Neuphoria Therapeutics acquire Scancell?
Neuphoria Therapeutics's acquisition of Scancell was reported on July 24, 2026. Scancell Holdings is set to merge with Neuphoria Therapeutics in a reverse takeover. This merger allows Scancell to list on Nasdaq while retaining significant ownership. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Scancell do?
The company’s innovative products target post-translational modifications of proteins and lipids. It is publicly traded (SCNLD), operating in Biotechnology, and is based in Oxford.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.